Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 478 All time
- Disclosed funding
- $19.6B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| RC Rainbow CropsCompany profile Combines AI, multiplex genome editing, and precision breeding to develop resilient crop varieties Combines AI, multiplex genome editing, and precision breeding to develop resilient crop varieties | €9.7M | Seed+Seed | Biotech, Agritech | Belgium | Investors | |
| RN Radical NumericsCompany profile Builds multimodal AI models that read, write, and design across DNA, RNA, and proteins Builds multimodal AI models that read, write, and design across DNA, RNA, and proteins | $50M | Seed | Biotech | United States | Investors | |
| NM Nanordica MedicalCompany profile Develops antibiotic-free wound dressing that prevents infection and promotes healing in chronic wounds Develops antibiotic-free wound dressing that prevents infection and promotes healing in chronic wounds | €1.6M | Seed | Biotech, Healthtech | Estonia | Investors | |
| S Develops ultrasound-mediated nonviral genetic medicines | $125M | Series B | Biotech | United States | Investors | |
| F FesariusTherapeuticsCompany profile Develops FDA-cleared hydrogel dermal regeneration templates for wound healing and reconstructive surgery Develops FDA-cleared hydrogel dermal regeneration templates for wound healing and reconstructive surgery | $20M | Series A | Biotech, Healthtech | United States | Investors | |
| A AntogenCompany profile Antogen provides immunopeptidomics services for drug discovery and translational research, identifying peptide–HLA ligands in biological samples. Antogen provides immunopeptidomics services for drug discovery and translational research, identifying peptide–HLA ligands in biological samples. | Undisclosed | Seed | Biotech | United States | Investors | |
| GM GT Medical TechnologiesCompany profile Develops bioresorbable radiotherapy implants for surgical treatment of operable brain tumors Develops bioresorbable radiotherapy implants for surgical treatment of operable brain tumors | $100M | Series ESeries C+ | Biotech, Healthtech | United States | Investors | |
| EB Element BiosciencesCompany profile Develops genomic and multiomic sequencing platforms for research, translational science, and diagnostics Develops genomic and multiomic sequencing platforms for research, translational science, and diagnostics | $175M | Series ESeries C+ | Biotech | United States | Investors | |
| RB Rejuvenate BioCompany profile Develops gene therapies for age-related and chronic diseases in animals and humans Develops gene therapies for age-related and chronic diseases in animals and humans | $6M | StrategicUndisclosed | Biotech | United States | Investors | |
| CT City TherapeuticsCompany profile City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas. City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas. | $99.5M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.